Compare Amphastar Pharmaceuticals Inc (AMPH) vs Veritone Inc (VERI) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Veritone (VERI) trades at $1.18, down 1.67% on the day, amid a bearish technical outlook and significant financial challenges. The company reported a net loss of $111.73 million in 2025, with negative profit margins and cash flow from operations. Recent news is dominated by multiple securities class action lawsuits alleging accounting irregularities, with a key deadline of July 20, 2026.

The outlook remains highly risky due to persistent losses, legal overhangs, and negative investor sentiment. While analyst consensus suggests substantial upside to a $5.25 price target, fundamental weaknesses and ongoing litigation present severe headwinds for shareholder value recovery in the near term.